5,383 DaVita Inc. $DVA Shares Sold by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC reduced its position in DaVita Inc. (NYSE:DVA) by 15.1% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 30,339 shares of the company’s stock after selling 5,383 shares during the quarter. Nisa Investment Advisors LLC’s holdings in DaVita were worth $5,307,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Value Investment Professionals LLC lifted its position in shares of DaVita by 2.0% during the second quarter. Value Investment Professionals LLC now owns 2,501 shares of the company’s stock worth $556,000 after purchasing an additional 50 shares in the last quarter. Kesler Norman & Wride LLC grew its holdings in shares of DaVita by 0.8% in the first quarter. Kesler Norman & Wride LLC now owns 6,816 shares of the company’s stock valued at $1,048,000 after purchasing an additional 55 shares in the last quarter. State of Alaska Department of Revenue grew its holdings in shares of DaVita by 1.9% in the third quarter. State of Alaska Department of Revenue now owns 3,206 shares of the company’s stock valued at $560,000 after purchasing an additional 60 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its holdings in shares of DaVita by 4.1% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,915 shares of the company’s stock valued at $426,000 after purchasing an additional 76 shares in the last quarter. Finally, CoreCap Advisors LLC increased its stake in DaVita by 161.7% during the 3rd quarter. CoreCap Advisors LLC now owns 157 shares of the company’s stock worth $27,000 after buying an additional 97 shares during the period. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

DaVita Stock Performance

Shares of DaVita stock opened at $183.55 on Friday. The business has a 50-day simple moving average of $180.60 and a 200-day simple moving average of $191.69. DaVita Inc. has a one year low of $101.00 and a one year high of $247.49. The company has a market cap of $11.71 billion, a PE ratio of 15.02, a P/E/G ratio of 0.48 and a beta of 0.80.

DaVita (NYSE:DVA) last issued its earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share for the quarter, beating the consensus estimate of $3.88 by $0.14. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The firm had revenue of $3.55 billion for the quarter, compared to analysts’ expectations of $3.50 billion. During the same quarter last year, the company earned $2.95 earnings per share. The firm’s revenue was up 5.2% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, sell-side analysts predict that DaVita Inc. will post 14.57 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on DVA. Oppenheimer set a $220.00 target price on shares of DaVita in a report on Friday, August 7th. Barclays boosted their price target on shares of DaVita from $218.00 to $224.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 5th. Raymond James Financial set a $220.00 price target on shares of DaVita in a research note on Friday, August 7th. Truist Financial cut their price objective on DaVita from $250.00 to $215.00 and set a “hold” rating on the stock in a research report on Friday, August 7th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $265.00 price objective on shares of DaVita in a research note on Wednesday, August 5th. Four investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $233.43.

DaVita Profile

DaVita Inc (NYSE: DVA) is a health care services company focused on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis treatments for people with chronic kidney failure, including in-center hemodialysis, home dialysis and related clinical support services.

DaVita also offers integrated kidney care programs intended to support patients across the stages of chronic kidney disease. Its services may include care coordination, disease management, education, transplant support and other services designed to improve clinical outcomes and help manage the needs of patients with complex kidney conditions.

The company operates a network of dialysis centers and related facilities in the United States and serves patients in select international markets.